Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

Official Title: “A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients Iwth Stage 1 or Stage 2 Hypertension”

The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.

Intervention(s) in this Clinical Trial

• Drug: telmisartan 80 mg / hydrochlorothiazide 25 mg
• Drug: valsartan 160 mg / hydrochlorothiazide 25 mg
• Drug: placebo

Primary Measures

• Change from baseline in mean seated trough cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period
  • Time Frame: 8 week
    

Secondary Measures

• Change from baseline in seated peak (1 and 3 hours post dose) cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period
  • Time Frame: 8 week
    

Inclusion Criteria:

• 1. Ability to provide written informed consent.
• 2. Age 18 years or older
• 3. Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)
• 4. Seated cuff DBP of ? 95 mmHg at Visit 2 (baseline)

Exclusion Criteria:

• 1. Pre-menopausal women (last menstruation ? 1 year prior to start of run-in period) who:
• 1. are not surgically sterile and/or
• 2. are nursing or pregnant
• 3. are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do
• NOT agree to submit to periodic pregnancy testing during participation in studies of > 3-months duration. Acceptable methods of birth control include oral, implantable, transdermal, or injectable contraceptives, and Intra-Uterine
• Device (IUD).
• 2. Known or suspected secondary hypertension.
• 3. Mean seated SBP >= 180 mmHg or mean seated DBP >= 120 mmHg during any clinic visit prior to randomization.
• 4. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
• 1. SGPT (ALT) or SGOT (AST) > 2 times the upper limit of normal range, or 2. Serum creatinine > 3.0 mg/dL or creatinine clearance < 0.6 ml/sec.
• 5. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one kidney.
• 6. Clinically relevant hypokalemia or hyperkalemia.
• 7. Uncorrected volume depletion.
• 8. Uncorrected sodium depletion.
• 9. Primary aldosteronism.
• 10. Hereditary fructose intolerance.
• 11. Biliary obstructive disorders, cholestatis or moderate to severe hepatic in sufficiency.
• 12. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
• 13. History of drug or alcohol dependency within six months prior to start of run-in period.
• 14. Chronic administration of any medications known to affect blood pressure, exc

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Boehringer Ingelheim Pharmaceuticals Industry

Overall Clinical Trial Officials and Contacts

Boehringer Ingelheim Study Chair Boehringer Ingelheim Pharmaceuticals  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00168779

Study ID Number: 502.476

ClinicalTrials.gov Identifier: NCT00168779

Health Authority: United States: Food and Drug Administration